Saturday 17 October 2026
Export RMD’s income statement to Excel — free account
ResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
238.97
3.26
−1.35%
Follow RMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
18.63 | 21.58 | 23.73 | 27.90 |
+8 more quarters Free account |
P/S ratio |
5.02 | 5.89 | 6.51 | 7.61 | |
P/FCF ratio |
17.41 | 18.79 | 19.77 | 22.78 | |
P/Operating CF |
62.38 | 58.88 | 103.40 | 87.50 | |
P/B ratio |
4.31 | 5.03 | 5.56 | 6.54 | |
Price to Tangible BV |
8.80 | 10.79 | 12.34 | 15.21 | |
EV/Sales |
4.83 | 5.66 | 6.32 | 7.43 | |
EV/EBITDA |
12.81 | 14.55 | 16.52 | 19.67 | |
EV/Operating CF |
15.11 | 16.60 | 17.82 | 20.73 | |
EV/FCF |
16.76 | 18.07 | 19.20 | 22.22 | |
Quick Ratio |
1.80 | 1.97 | 1.93 | 1.82 | |
Current Ratio |
3.10 | 3.01 | 3.06 | 2.89 | |
Net Debt/EBITDA |
(2.12) | (2.21) | (1.83) | (1.93) | |
Debt/Assets |
4.45% | 4.60% | 4.75% | 4.92% | |
Debt/Equity |
0.06 | 0.06 | 0.06 | 0.07 | |
Asset Turnover |
0.66 | 0.68 | 0.69 | 0.68 | |
Operating CF/Net income |
1.19 | 1.39 | 0.87 | 1.31 | |
Capex/Depreciation |
(1.04) | (0.57) | (0.55) | (0.79) | |
Interest Coverage |
(21.48) | (40.68) | (61.85) | (50.78) | |
Research and Development Expense of Revenue |
7.22% | 6.59% | 6.39% | 6.54% | |
Selling, General and Administrative Expense of Revenue |
20.24% | 19.96% | 19.57% | 19.41% | |
Intangible Assets out of Total Assets |
0.38 | 0.39 | 0.41 | 0.42 | |
Share Based Compensation of Revenue |
1.88% | 1.87% | 2.03% | 1.58% | |
Graham Net Nets |
0.07 | 0.05 | 0.05 | 0.04 | |
Graham Number |
103.20 | 102.24 | 99.49 | 96.14 | |
Earnings Yield |
5.37% | 4.63% | 4.21% | 3.58% | |
Free Cash Flow Yield |
5.74% | 5.32% | 5.06% | 4.39% | |
Revenue per Share |
10.06 | 9.85 | 9.76 | 9.14 | |
Operating CF per Share |
3.12 | 3.81 | 2.33 | 3.13 | |
Capex per Share |
(0.39) | (0.27) | (0.24) | (0.31) | |
Free Cash Flow per Share |
2.73 | 3.54 | 2.09 | 2.82 | |
Cash per Share |
10.10 | 11.43 | 9.72 | 9.47 | |
Shareholders Equity per Share |
45.25 | 44.67 | 43.34 | 41.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
45.25 | 44.67 | 43.34 | 41.87 | |
Free Cash Flow |
397.38 | 514.54 | 305.19 | 411.54 | |
Working Capital |
2,929.63 | 2,712.85 | 2,570.69 | 2,370.23 | |
Capital Expenditures |
(57.25) | (39.59) | (34.55) | (45.78) | |
Net Current Asset Value |
1,944.18 | 1,771.69 | 1,636.31 | 1,438.65 | |
EV/EBIT |
14.46 | 16.58 | 18.76 | 22.38 | |
Capex to Sales |
0.04 | 0.03 | 0.02 | 0.03 | |
Price to Operating Income |
15.03 | 17.24 | 19.31 | 22.94 | |
| Other line items | |||||
Average Receivables |
987.86 | 953.33 | 922.79 | 859.23 | |
Average Payables |
293.54 | 247.93 | 235.36 | 258.03 | |
Average Inventory |
936.76 | 887.26 | 902.07 | 931.89 | |
Average Assets |
8,570.17 | 8,175.55 | 7,822.35 | 7,765.38 | |
Average Common Equity |
6,276.63 | 6,019.02 | 5,786.94 | 5,658.15 |
Columns are period end dates